Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/01/17
End: 04/24/24
Due: 04/24/25
Phase: N/A
Priority: Normal
Start: 05/31/24
End: 08/31/27
Due: 08/31/28
Phase: N/A
Priority: Normal
Start: 11/05/20
End: 12/20/25
Due: 12/20/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma | NCT03097328 | Bradley A. McGregor, MD | user2@example.com | None | 2017-08-01 | 2024-04-24 | 2025-04-24 | - | - | 2025-07-14 |
| Avelumab, Palbociclib and Axitinib in Advanced RCC | NCT05176288 | Bradley A. McGregor, MD | user2@example.com | None | 2024-05-31 | 2027-08-31 | 2028-08-31 | - | - | 2025-07-14 |
| Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | NCT04413123 | Bradley A. McGregor, MD | user2@example.com | None | 2020-11-05 | 2025-12-20 | 2026-12-20 | - | - | 2025-07-14 |